ePGA

ePGA translates individual genotype data into pharmacogenomic haplotypes, infers diplotypes and phenotypes, and aligns results with clinical pharmacogenomics guidelines to support interpretation of gene–drug interactions.

Key Features:

• Personalized Genotype-to-Phenotype Translation: Matches individual genotype profiles with pharmacogenomic gene haplotypes to infer corresponding diplotype and phenotype profiles.
• Haplotype Variation Consideration: Addresses extensive haplotype variation associated with drug metabolism rather than relying on simplistic genotype-variant matches.
• Clinical Guideline Integration: Aligns genotype-phenotype translations with state-of-the-art clinical pharmacogenomics guidelines.
• Customizable Translation: Allows translation customization based on subsets of variants of particular clinical interest.
• Dynamic Knowledge Base Updates: Supports updates to the knowledge base with novel pharmacogenomics findings and guideline changes.
• Comprehensive Summary Statistics: Provides summary statistics alongside genotype-phenotype translations for analytical interpretation.

Scientific Applications:

• Pharmacogenomics research: Facilitates studies of gene–drug interactions by translating genotypes to phenotypic outcomes.
• Personalized medicine: Supports individualized therapeutic decision making by providing genotype-informed phenotype predictions aligned with clinical guidelines.
• Drug metabolism and efficacy studies: Enables analysis of haplotype-driven variation in drug metabolism and response across populations.

Methodology:

Matches individual genotype profiles to pharmacogenomic haplotypes to infer diplotypes and phenotypes, leverages variant data from the 1000 Genomes Project for demonstration and population-level analyses, and allows knowledge-base updates with novel PGx findings while producing summary statistics.